Single-cell sequencing in precision management of chronic myeloid leukemia

Abstract

Single-cell sequencing technology provides a high-resolution perspective for the precision diagnosis and treatment of chronic myeloid leukemia (CML). Cellular and molecular heterogeneity in CML is closely associated with tyrosine kinase inhibitor resistance, residual disease, and disease progression. However, the averaged signals generated by conventional bulk sequencing limit the identification of minor resistant clones, state-dependent leukemia stem cell (LSC) programs, and complex microenvironmental interactions. This review summarizes frontier applications of single-cell RNA sequencing and related single-cell omics technologies in CML, including molecular mechanism analysis, tumor microenvironment profiling, resistance mechanism exploration, biomarker discovery, and the translation of these findings into risk stratification, treatment monitoring, and individualized therapeutic strategies. By integrating recent global research findings, this review discusses the value of single-cell technology in revealing the functional heterogeneity of LSCs and provides a balanced perspective on the future integration of spatial multi-omics, artificial intelligence-assisted analysis, and clinical decision systems. The aim is to clarify how CML diagnosis and treatment may move from empiric disease monitoring toward a more precise, single-cell-informed model while acknowledging current technical, economic, regulatory, and validation barriers.

Keywords

Single-cell sequencing / chronic myeloid leukemia / stem cells / tumor microenvironment / diagnosis / treatment / drug resistance

References

[1] Jabbour E.Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring.Am J Hematol2024;99:2191-212

[2] Rowley JD.A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining.Nature1973;243:290-3

[3] Faderl S,Estrov Z,Kurzrock R.The biology of chronic myeloid leukemia.N Engl J Med1999;341:164-72

[4] Mandanas R,Gharehbaghi K.Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.Blood1993;82:1838-47

[5] Minciacchi VR,Krause DS.Chronic myeloid leukemia: a model disease of the past, present and future.Cells2021;10:117 PMCID:PMC7827482

[6] Raitano AB,Hambuch TM.The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.Proc Natl Acad Sci USA1995;92:11746-50 PMCID:PMC40479

[7] Stein SJ.NF-κB suppresses ROS levels in BCR-ABL+ cells to prevent activation of JNK and cell death.Oncogene2011;30:4557-66 PMCID:PMC3165082

[8] Tam WF,Chen J.Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.Blood2008;112:1981-92 PMCID:PMC2518899

[9] He F,Gao B.A proteogenomic gene signature defines prognostic subgroups highlighting PI3K/AKT/mTOR signaling pathway as a therapeutic vulnerability in myeloid malignancies.Cell Commun Signal2025;24:61 PMCID:PMC12853910

[10] Mohammadhosseini M,Duvall A.Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder.Sci Transl Med2025;17:eadn9832 PMCID:PMC11912227

[11] Huang X,Kantarjian H.Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Cancer2012;118:3123-7 PMCID:PMC3342429

[12] Weisberg E,Breitenstein W.Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Cancer Cell2005;7:129-41

[13] Shah NP,Lee FY,Norris D.Overriding imatinib resistance with a novel ABL kinase inhibitor.Science2004;305:399-401

[14] Druker BJ.Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia.J Clin Investig2000;105:3-7 PMCID:PMC382593

[15] Jabbour E,Haddad FG.Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis.Am J Hematol2022;97:1413-8 PMCID:PMC11837974

[16] Krishnan V,Nawaz Z.A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.Blood2023;141:2738-55

[17] Zhang W,Weng L.Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia.Aging2020;12:25337-55 PMCID:PMC7803567

[18] Komic H,Wennström L.Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia.Haematologica2025;110:117-28 PMCID:PMC11694111

[19] Stengel A,Kühn C.Potential factors underlying the progression of RUNX1-mutated MDS to AML.Cancer Genet2025;294-5:181-3

[20] Li X,Zhang Y.FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Cell Rep Med2026;7:102686 PMCID:PMC13006436

[21] Cui Y,Ji J.Dynamic single-Cell RNA-seq reveals mechanism of selinexor-resistance in chronic myeloid leukemia.Int Immunopharmacol2024;134:112212

[22] Liu H,Karsidag M,Wang P.Technical and biological biases in bulk transcriptomic data mining for cancer research.J Cancer2025;16:34-43 PMCID:PMC11660120

[23] Munje C.Exploring stem cell heterogeneity in chronic myeloid leukemia.Trends Cancer2018;4:167-9

[24] Zheng Y.Spatial RNA sequencing methods show high resolution of single cell in cancer metastasis and the formation of tumor microenvironment.Biosci Rep2023;43:BSR20221680 PMCID:PMC9950536

[25] Frankhouser DE,Fu YH.Longitudinal single cell RNA-sequencing reveals evolution of micro- and macro-states in chronic myeloid leukemia.Syst Biol2025;2025.05.14.653262

[26] Cho J,Hemberg M.Joint analysis of mutational and transcriptional landscapes in human cancer reveals key perturbations during cancer evolution.Genome Biol2024;25:65 PMCID:PMC10921788

[27] Zhu L,Zhou J.Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review.Ann Hematol2025;104:6045-51 PMCID:PMC12672611

[28] Dawson A,Prasad B.Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche.Nat Commun2024;15:1090 PMCID:PMC10844594

[29] Zhuo C,Zhao X.Single-cell sequencing reveals the expansion and diversity of T cell subsets in the bone marrow microenvironment of chronic myeloid leukemia.Genes Dis2025;12:101626 PMCID:PMC12221761

[30] Svensson V,Teichmann SA.Exponential scaling of single-cell RNA-seq in the past decade.Nat Protoc2018;13:599-604

[31] Hwang B,Bang D.Single-cell RNA sequencing technologies and bioinformaticspipelines.Exp Mol Med2018;50:1-14 PMCID:PMC6082860

[32] Shaffer SM,Torborg SR.Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance.Nature2017;546:431-5 PMCID:PMC5542814

[33] Tang F,Wang Y.mRNA-Seq whole-transcriptome analysis of a single cell.Nat Methods2009;6:377-82

[34] Salmen F,Kaminski TS.High-throughput total RNA sequencing in single cells using VASA-seq.Nat Biotechnol2022;40:1780-93 PMCID:PMC9750877

[35] Hagemann-Jensen M,Chen P.Single-cell RNA counting at allele and isoform resolution using Smart-seq3.Nat Biotechnol2020;38:708-14

[36] Gierahn TM,Hughes TK.Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput.Nat Methods2017;14:395-8 PMCID:PMC5376227

[37] Fan HC,Fodor SPA.Combinatorial labeling of single cells for gene expression cytometry.Science2015;347:1258367

[38] Wang X,Zhang Q,Zhang Z.Direct comparative analyses of 10X genomics chromium and smart-Seq2.Genom Proteom Bioinform2021;19:253-66 PMCID:PMC8602399

[39] Warfvinge R,Dhapola P.Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.eLife2024;12:RP92074

[40] Li L,Saeed BR.High-dimensional spatiotemporal single-cell atlas and 3D imaging of the bone marrow microenvironment during CML progression.Blood2026;147:2648-65 PMCID:PMC13277661

[41] Mustjoki S,Barbany G.Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.Leukemia2013;27:1520-6

[42] Sloma I,Saw KM.Genotypic and functional diversity of phenotypically defined primitive hematopoietic cells in patients with chronic myeloid leukemia.Exp Hematol2013;41:837-47

[43] Giustacchini A,Barkas N.Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.Nat Med2017;23:692-702

[44] Warfvinge R,Sommarin MNE.Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.Blood2017;129:2384-94 PMCID:PMC5484462

[45] Ma J,Talburt J,Weissman SM.Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid leukemia.Int J Mol Sci2022;23:14335 PMCID:PMC9695508

[46] Yin Z,Ge L.Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.Int J Biol Sci2023;19:1211-27 PMCID:PMC10008703

[47] Patterson SD.The bone marrow immune microenvironment in CML: treatment responses, treatment-free remission, and therapeutic vulnerabilities.Curr Hematol Malig Rep2023;18:19-32 PMCID:PMC9995533

[48] Nievergall E,Kok CH.TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.Leukemia2016;30:1263-72

[49] Reynaud D,Barry-Holson K.IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.Cancer Cell2011;20:661-73 PMCID:PMC3220886

[50] Buenrostro JD,Zaba LC,Greenleaf WJ.Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position.Nat Methods2013;10:1213-8 PMCID:PMC3959825

[51] Chimge N,Nguyen C.A deeply quiescent subset of CML LSC depend on FAO yet avoid deleterious ROS by suppressing mitochondrial complex I.Curr Mol Pharmacol2023;17:e060923220758

[52] Yu G,Chen X.Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.Leukemia Lymphoma2022;63:2604-15

[53] Imeri J,Marcoux P.Case report: long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): molecular evidence of an immune surveillance.Front Oncol2023;13:1117781 PMCID:PMC10062417

[54] Bertacchini J,Mediani L,Marmiroli S.Inhibition of Ras-mediated signaling pathways in CML stem cells.Cell Oncol2015;38:407-18 PMCID:PMC13004246

[55] Zhou J,Leng J.DNA methylation-mediated differential expression of DLX4 isoforms has opposing roles in leukemogenesis.Cell Mol Biol Lett2022;27:59 PMCID:PMC9327205

[56] Holyoake TL.The chronic myeloid leukemia stem cell: stemming the tide of persistence.Blood2017;129:1595-606

[57] Perry JM,Roy A.Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells.Nat Cell Biol2020;22:689-700

[58] Desterke C,Hwang JW,Turhan AG.Embryonic program activated during blast crisis of chronic myelogenous leukemia (CML) implicates a TCF7L2 and MYC cooperative chromatin binding.Int J Mol Sci2020;21:4057 PMCID:PMC7312032

[59] Veenstra J,Yao Y,Ozog D.Research techniques made simple: use of imaging mass cytometry for dermatological research and clinical applications.J Investig Dermatol2021;141:705-12.e1 PMCID:PMC7995633

[60] Cheung TK,Bayer FP,Kuster B.Defining the carrier proteome limit for single-cell proteomics.Nat Methods2020;18:76-83

[61] Coorens THH,Choi YA.The somatic mosaicism across human tissues network.Nature2025;643:47-59

[62] Rao A,França GS.Exploring tissue architecture using spatial transcriptomics.Nature2021;596:211-20 PMCID:PMC8475179

[63] Kuznetsova OA,Lebedeva AA.Comprehensive molecular profiling in MOTION study.Cancer Genet2025;296-7:45-52

[64] Lopez R,Cole MB,Yosef N.Deep generative modeling for single-cell transcriptomics.Nat Methods2018;15:1053-8 PMCID:PMC6289068

[65] Cui H,Maan H.scGPT: toward building a foundation model for single-cell multi-omics using generative AI.Nat Methods2024;21:1470-80

[66] Borra S,Welner RS.An AI-enabled single-cell transcriptomic analysis pipeline for gene signature discovery in natural killer cells linked to remission outcomes in chronic myeloid leukemia.Biology2026;15:588 PMCID:PMC13072394

[67] Huuhtanen J,Theodoropoulos J.Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.Leukemia2023;38:109-25 PMCID:PMC10776410

[68] Lei Y,Xu J.Applications of single-cell sequencing in cancer research: progress and perspectives.J Hematol Oncol2021;14:91 PMCID:PMC8190846

[69] Hu Y,Sheu K,Fan S.Single cell multi-omics technology: methodology and application.Front Cell Dev Biol2018;6:28 PMCID:PMC5919954

[70] Thakur RK.Insights from single-cell omics: cellular heterogeneity as a foundation of clinical outcome in chronic myeloid leukemia.Blood2026;147:485-96